ABSTRACT
tion) can be ascribed to the higher r1 relaxivity of gadobenate in vivo, 5 which translates into greater signal-intensity (SI) enhancement on T1-weighted images. An early study in 23 patients suggested that 0.1-mmol/kg gadobenate may provide superior contrast enhancement compared with 0.1-mmol/kg gadoterate meglumine (Dotarem; Guerbet, Aulnay-sous-Bois, France), another gadolinium-based contrast agent (GBCA) with lower r1 relaxivity. 6 However, the sample size was too small to draw firm conclusions. Another more recent study has demonstrated superiority in the quality of visualization of brain lesions for a threequarter (0.075-mmol/kg) dose of gadobenate over a full 0.1-mmol/kg dose of gadoterate in patients undergoing cranial MR imaging. 7 These results suggest that better or similar SI enhancement and similar imaging performance may be achieved with a reduced gadobenate dose. The purpose of this multicenter, multinational study in 177 patients referred for morphologic brain MR imaging was first to confirm previous findings 6 in demonstrating imaging superiority for 0.1-mmol/kg gadobenate over 0.1-mmol/kg gadoterate in a properly sized and powered clinical study; and second, to ascertain whether half-dose (0.05-mmol/kg) gadobenate provides similar diagnostic information to full-dose (0.1-mmol/kg) gadoterate when these agents are administered in 2 otherwise identical MR imaging examinations at 1.5T using a rigorous, double-blind, randomized, intraindividual, crossover study design.
MATERIALS AND METHODS
The study was compliant with the Health Insurance Portability and Accountability Act, was conducted according to Good Clinical Practice standards, and was registered at www.clinicaltrials. gov (NCT02070380). Ethics committee approval was obtained from all investigating centers, and all patients signed an approved informed consent form before enrollment.
Patients
One hundred seventy-seven patients referred for contrast-enhanced MR imaging for known or suspected brain tumors were prospectively enrolled in a consecutive manner at 14 participating centers between February 2014 and February 2015 and underwent at least 1 contrast-enhanced MR imaging examination. Two centers enrolled 30 patients each, while a further 8 centers enrolled between 7 and 26 patients. The remaining 4 centers enrolled between 1 and 4 patients. Patients were ineligible if they received any investigational drug within 30 days before study agent administration. Subjects were also excluded if they were to receive any treatment between the 2 examinations that could affect lesion visualization (eg, radiation therapy, steroids, or chemotherapy).
Patients were also ineligible if they were pregnant or nursing or had impaired renal function, congestive heart failure, claustrophobia, history of reaction to prior gadolinium contrast agent administration, a cardiac pacemaker, or other contraindications to MR imaging. The 177 enrolled patients were prospectively randomized to 1 of 2 study arms by means of a central computer-generated randomization code list that was provided to each site before patient enrollment for the assignment of a study arm and an investigational product. To maintain the study blind, a drug-dispensing person was selected at each site for the duration of the study. The drug-dispensing person was responsible for dispensing the 2 investigational products to the appropriate personnel, according to the randomization list. Arm 1 saw 70 patients (29 men 
MR Imaging
MR imaging was performed on 1.5T systems from several vendors (Avanto/Aera, n ϭ 67; Siemens, Erlangen, Germany; Achieva/ Intera, n ϭ 66; Philips Healthcare, Best, the Netherlands; HDxt/ Excite, n ϭ 44; GE Healthcare, Milwaukee, Wisconsin) by using a multichannel head coil. Despite the benefits of 3T systems, particularly for advanced imaging techniques, 1.5T systems were used in this study because they are still more commonly used throughout the United States, Europe, and other areas worldwide.
A rigorously controlled imaging protocol comprising T1-weighted spin-echo (T1SE), T2-weighted fast spin-echo , and T2-weighted FLAIR acquisitions before contrast injection and T1SE and 3D T1-weighted high-resolution gradient-echo (T1GRE) acquisitions after injection ensured protocol uniformity across sites and within individual patients. Sequence parameters varied within predefined ranges necessitated by the use of different imaging systems. However, the same MR imaging scanner, imaging planes, section prescriptions, and sequence parameters were used for both examinations in each patient. Scan parameters were as follows: for the T1SE sequence: TR ϭ 400 -707 ms, TE ϭ 8 -15 ms, excitations ϭ 1-2, section thickness ϭ 4 -5 mm, FOV ϭ 22 ϫ 17-24 ϫ 24 cm; for the T1GRE sequence: TR ϭ 6 -2200 ms, TE ϭ 2-5 ms, flip angle ϭ 8°-30°, excitations ϭ 0.8 -1, section thickness ϭ 1-3 mm, FOV ϭ 23 ϫ 18 -29 ϫ 29 cm. Parallel imaging was not used for any patient. Axial scans were all acquired along the inferior callosal plane to ensure image comparability between scans within patient comparisons and across patients.
IV contrast agent administration to patients in Arm 1 was performed identically for both examinations at 0.1 mmol/kg of body weight (0.2 mL/kg for both agents) by using either manual bolus injection (n ϭ 57) or a power injector (n ϭ 13). Contrast administration to patients in Arm 2 was performed at 0.1 mmol/kg for gadoterate but at 0.05 mmol/kg (0.1 mL/kg) for gadobenate, again by manual bolus injection (n ϭ 83) or a power injector (n ϭ 24). All injections were followed by a saline flush of up to 30 mL. To maintain the study blind, an independent drugdispensing person administered each agent in the order determined by the randomization list.
Postcontrast image acquisition began at a prespecified time between 3 and 10 minutes after injection but could vary within this range depending on the site-specific protocol. However, the timing and order of postcontrast sequences were mandated to be identical for both examinations within each patient. The interval between MR imaging examinations was Ͼ48 hours to avoid carryover effects but Ͻ14 days to minimize the chance of disease progression.
Image Evaluation
All images were evaluated by 3 independent neuroradiologists (A.B., C.C., S.L.; 34, 35, and 7 years of neuroradiology experience, respectively) who were unaffiliated with the study centers and blinded to the contrast agent used, patient clinical and radiologic information, and interpretations by on-site investigators. Each reader evaluated all patient images independently on a multimonitor workstation (AquariusNET Server, Version 4.4.1.4; TeraRecon, San Mateo, California) in terms of qualitative and quantitative end points.
Qualitative and quantitative assessment of images from each patient in each study arm was performed with images presented in global matched-pairs fashion. For each randomized patient number, all images from examination 1 were displayed simultaneously with the images from examination 2. Each reader could perform all routine interactive image manipulation functions (ie, window/ level, zoom, pan) on both image sets. If the postinjection images from either examination were considered technically inadequate by any of the 3 readers (eg, if artifacts compromised interpretability), no further assessment was performed for that patient by that reader. Once the readers' assessments were recorded and signed on an electronic case report form, the data base for that reading was automatically locked.
Qualitative Assessment
Technically adequate images were evaluated qualitatively for diagnostic information and scored in terms of overall diagnostic preference and quality of the following: 1) lesion border delineation, 2) definition of extent of disease, 3) visualization of lesion internal morphology, and 4) lesion contrast enhancement compared with surrounding normal tissue. All assessments were performed by using 3-point scales from Ϫ1 (examination 1 better) through 0 (examinations equal) to ϩ1 (examination 2 better). For the various end points, superiority for 1 examination was recorded if it allowed better separation of Ն1 lesion from surrounding tissue, structures, or edema; better definition of lesion extent; clearer depiction of intralesion features; better contrast between lesions and surrounding normal tissue; or the ability to identify Ն1 lesion seen only on that examination.
Quantitative Assessment
Quantitative evaluation was also performed by each reader, independently, by using a simultaneous matched-pairs approach. SI measurements were made by using ROIs positioned on up to 3 enhancing lesions per patient identified on postcontrast images from both examinations and on areas of normal brain parenchyma in the same section. To ensure that ROIs of equal size (placed to include the largest possible area) were positioned at identical coordinates on all corresponding image sets, each ROI placed on the selected postinjection image from one examination appeared simultaneously on the corresponding image from the other examination. Minor adjustments to the ROI position were permitted to allow for slight differences in patient alignment, always taking care to avoid the inclusion of vessels. When multiple lesions were present, ROIs were placed on up to 3 of the largest, most conspicuous lesions. SI values determined on a pixel-bypixel basis were used to calculate the percentage enhancement (E%) of lesions and the postcontrast-precontrast lesion-to-background ratio (LBR) on T1SE sequences by using the equations below:
E% ϭ SI of lesion ͑postcontrast͒ Ϫ SI of lesion ͑precontrast͒ SI of lesion ͑precontrast͒ ϫ 100, LBR ϭ SI of lesion SI of brain
Safety Assessments
Monitoring for adverse events was performed from the time the patient signed the informed consent form until 24 hours after administration of the first study agent and then from the moment the second study agent was administered until 24 hours after administration of the second agent. Events were classified as serious according to the definitions of the US Food and Drug Administration in the Code of Federal Regulation Title 21, Volume 5 Revised, as of April 1, 2014 (http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/cfrsearch.cfm?frϭ312.32). Decisions on event severity and its relationship to the study agent (has reasonable possibility or not) were made by the investigating radiologist.
Statistical Analysis
Power determination was based on the primary efficacy assumption that gadobenate is superior to gadoterate according to reader preference. Sample sizes were determined (nQuery Advisor, Version 7.0; Statistical Solutions, Cork, Ireland) on the basis of the results of a previous study that had a similar crossover design. 3 For the full-dose gadobenate arm (Arm 1) assuming an "equal" response in 50% of cases, a ratio of preference for either agent of 4:1, and an effect size of 0.18, evaluation of 61 subjects was considered necessary to demonstrate the difference in preference with 85% of power at an ␣ level of .05. Considering a drop-out rate of 15%, enrollment of approximately 72 subjects was needed. For the halfdose gadobenate arm (Arm 2), again assuming an "equal" response in 50% of cases but with a ratio of preference for either agent of 3:1 and an effect size of 0.125, evaluation of 88 subjects was considered necessary for 85% of power at an ␣ level of .05. If one assumed a drop-out rate of 15%, enrollment of approximately 104 subjects was needed.
Differences in demographic characteristics between the 2 administration orders within each study arm were tested by using the t test for continuous variables or the Fisher exact test for categoric variables.
Analysis of blinded-reader evaluations was performed by using the statistical software package SAS, Version 9.2 (SAS Institute, Cary, North Carolina). The distribution of reader preferences in diagnostic information end points was tested statistically by using the Wilcoxon signed rank test. Interreader agreement for diagnostic findings was presented as percentage agreement for the 3 readers and assessed by using generalized statistics. Agreement Differences between gadobenate and gadoterate in terms of quantitative parameters were analyzed by using a mixed-effects model. The change from predose was the response variable, and factors included in the model were patient, sequence, study agent, and predose score; "patient" nested within "sequence" was the random effect. "Study period" was also included to test for potential carryover effects. The Fisher exact test was used to compare the incidence of adverse events for the 2 agents. All statistical tests were conducted at a significance level of P Ͻ .05.
RESULTS

Patients
All 177 enrolled patients who underwent at least 1 contrast-enhanced MR imaging examination were included in the overall safety population. Seven patients randomized to Arm 1 and 11 patients randomized to Arm 2 were excluded from efficacy evaluations because of protocol violations. These 18 patients included 10 who prematurely discontinued after the first examination 
There were no meaningful betweensequence differences in either study arm for sex (P ϭ 1.0, P ϭ .841; Arms 1 and 2, respectively), age (P ϭ .634, P ϭ .038), age group (18 -64 years, Ն65 years; P ϭ .274, P ϭ .283), weight (P ϭ .467, P ϭ .212), height (P ϭ .281; P ϭ .333), or race (P ϭ 1.0; P ϭ .496) distribution. The diagnoses of the 159 patients evaluated are presented in Table 1 . Intra-axial lesions represented approximately 71% of all patient diagnoses in Arm 1 and 79% of patient diagnoses in Arm 2. Tables 2 and 3 present the results of the 3 blinded readers for global diagnostic preference, lesion-border delineation, disease extent, internal morphology, and qualitative assessment of contrast enhancement for patients in Arms 1 and 2, respectively. Highly significant (P Յ .0023) superiority for gadobenate over gadoterate was noted by all readers for all qualitative assessments in patients receiving 0.1-mmol/kg doses of both agents (Table 2) . Conversely, no significant differences were noted by any reader for any qualitative parameter among patients receiving 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate (Table 3) . Agreement among the 3 blinded readers was high for all assessments in Arm 2, ranging from 63.4% of patients for global diagnostic preference to 84.9% of patients for visualization of internal lesion morphology. Slightly lower levels of agreement were noted for assessments in Arm 1. Examples of comparative enhancement between gadobenate and gadoterate are shown in Figs 1 and 2.
Qualitative Image Assessment
Quantitative Evaluation
Readers 1, 2, and 3 recorded lesion SI measurements relative to normal brain parenchyma for 63, 66, and 54 lesions (Arm 1) and 84, 89, and 78 lesions (Arm 2), respectively, on T1SE images and for 60, 61, and 51 lesions (Arm 1) and 82, 85, and 75 lesions (Arm 2), respectively, on T1GRE images. No lesions below 5 mm were measured by any of the readers. Analysis of quantitative SI data revealed no carryover effects across readers for any assessment (P Ͼ .05). The mean percentage signal enhancement of lesions on T1SE images was significantly (P Յ .0006) higher for gadobenate compared with gadoterate for all 3 readers in patients given 0.1-mmol/kg doses of both agents (Arm 1), while no meaningful differences were noted between 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate (Arm 2) (Fig 3A) .
Similar results were obtained for determinations of LBR ( Fig  3B) ; all 3 readers reported significantly (P Ͻ .0001) higher values for LBR with 0.1-mmol/kg gadobenate compared with 0.1-mmol/kg gadoterate, while no differences were noted between 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate. LBR findings on T1GRE images were similar: all 3 readers noted sig- 
Safety
In Arm 1, no patients (0/65; 0%) reported any adverse events that were considered related to 0.1-mmol/kg gadobenate, whereas 1 patient (1/70; 1.4%) reported 1 nonserious event (headache of moderate intensity) that was considered related to 0.1-mmol/kg gadoterate. In Arm 2, two patients (2/104; 1.9%) reported 1 adverse event each (dizziness of mild intensity, nausea of moderate intensity) that was considered related to 0.05-mmol/kg gadobenate, whereas 4 patients (4/105; 3.8%) reported 5 adverse events (injection site swelling, injection site pruritus, dysgeusia, headache, pruritus; all of mild intensity) that were considered related to 0.1-mmol/kg gadoterate. There were no significant differences in the incidence of adverse events in either arm (Arm 1: P ϭ 1.0000; Arm 2: P ϭ .6829). No serious adverse events were reported.
DISCUSSION
A recent independent determination of GBCA relaxivity values in human whole blood has shown that whereas most contrast agents approved for CNS imaging have r1 relaxivity values between 3.9 and 4.6 L ϫ mmol Ϫ1 ϫ seconds Ϫ1 at 1.5T, that of gadobenate is higher at 6.2 L ϫ mmol Ϫ1 ϫ seconds Ϫ1 . 5 That differences in r1 relaxivity reflect differences in diagnostic efficacy is borne out by evidence from numerous large-scale intraindividual crossover studies. [1] [2] [3] [4] [8] [9] [10] [11] These studies have shown that differences in SI enhancement and imaging performance reflect differences in r1 relaxivity and that the magnitude of the differences in SI enhancement a Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n ϭ 96 for reader 1, n ϭ 94 for reader 2, and n ϭ 95 for reader 3. Numbers in parentheses, except where noted, represent proportions of patients. b Wilcoxon signed rank test.
reflects the magnitude of the difference in r1 relaxivity. 12 Thus, large-scale, well-controlled, prospective clinical studies have found minimal differences between GBCAs with similar r1 relaxivity (eg, gadopentetate dimeglumine versus gadoteridol , and substantially improved SI enhancement and imaging performance for GBCAs with markedly higher r1 relaxivity (ie, gadobenate versus gadopentetate, 1,2 gadobenate versus gadodiamide, 3 gadobenate versus gadobutrol 4 ). Our results fully support these previous findings in confirming significantly superior imaging performance for gadobenate over gadoterate for both qualitative and quantitative enhancement when these agents are administered at equivalent approved doses of 0.1 mmol/kg body weight. In terms of diagnostic preference, readers 1, 2, and 3 preferred gadobenate in 31 (49.2%), 51 (82.3%), and 43 (69.4%) patients, respectively, compared with just 1, 2, and 2 patients for gadoterate (P Ͻ .0001, all readers), while highly significant (P Յ .0023) superiority was noted by all readers for all other qualitative parameters.
The importance of r1 relaxivity is highlighted by the quantitative results of this study compared with those of other studies. Thus, Anzalone et al 11 noted differences in percentage lesion enhancement and LBR of ϳ9.9% (97.962 versus 89.164) and ϳ3.6%
(1.596 versus 1.541), respectively, for gadobutrol versus gadoterate, which reflect a difference in r1 relaxivity of ϳ18% based on values determined by Shen et al. 5 In a comparison of gadobenate and gadobutrol, Siedl et al 4 reported differences in percentage lesion enhancement and LBR of 21.8%-24.7% and 21.4%-25.0%, respectively, which reflect a greater difference in r1 relaxivity of ϳ35%. In this study, we determined larger differences in percentage lesion enhancement and LBR of 27.6%-31.7% and 29.2%-38.1%, respectively, for equivalent doses of gadobenate and gadoterate, which reflect the still greater difference in r1 relaxivity of ϳ59%. Notably, in the study by Anzalone et al, 11 the slightly greater r1 relaxivity of gadobutrol compared with gadoterate led to improved imaging performance for gadobutrol for some, though not all, qualitative end points, and not all blinded readers demonstrated significant preference for gadobutrol.
Whereas the findings for Arm 1 might be considered unsurprising on the basis of previous findings, 1-4,6,13-16 those for Arm 2 might also have been anticipated on the basis of these same findings and those of Khouri Chalouhi et al, 7 who demonstrated a markedly better signal-to-noise ratio for a three-quarter dose of gadobenate compared with a full dose of gadoterate in 31 patients who underwent cranial MR imaging examinations with both agents. In our study, all 3 blinded, expert neuroradiologists expressed no preference for either half-dose gadobenate or full-dose gadoterate in most cases. In the few cases in which a reader ex- pressed preference, the number preferring 0.1-mmol/kg gadoterate was approximately equal to the number preferring 0.05-mmol/kg gadobenate. Similar findings were noted for quantitative enhancement measurements: no significant differences between 0.1-mmol/kg gadoterate and 0.05-mmol/kg gadobenate were noted either for mean percentage signal enhancement (apart from reader 2 who noted higher percentage enhancement with half-dose gadobenate) or for pre-to postdose changes in LBR. The interreader agreement for assessment of images was good in all cases (complete agreement for 63.4%-84.9% of patients among qualitative end points). Although the interreader agreement for lesion characterization was considered only moderate ( ϭ 0.44 -0.53), agreement was determined across 3 blinded readers rather than 2 as has been the case in some studies 17 ; clearly, complete agreement among 3 readers is less likely than complete agreement between 2. That the values and reader agreement in Arm 2 were higher than those in Arm 1 is due to the skewed distribution of preferences in Arm 1 with readers preferring gadobenate in many more patients than gadoterate. Skewed preferences of this type are known to lower values.
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In terms of clinical impact, the possibility of obtaining similar diagnostic information with a half-dose of gadobenate is potentially highly beneficial, not only in patients at risk of delayed adverse reactions such as nephrogenic systemic fibrosis and in light of recent concerns over intracranial gadolinium (Gd) 3ϩ deposition [19] [20] [21] [22] [23] [24] but also in patients who require multiple GBCA doses during either a short-term period (eg, patients undergoing intraoperative MR imaging) or an extended period (eg, patients requiring regular postoperative follow-up examinations). Although not evaluated in this study, half-dose gadobenate may also be of value in patients who require long-term routine evaluation of disease evolution (eg, patients with multiple sclerosis). In this latter case, a clear understanding of the differences between GBCAs in terms of relaxivity and enhancement potential is fundamental to avoid misinterpretation of imaging findings (ie, to avoid interpretations of disease progression or therapy response, which, in reality, may be due solely to the different enhancement potential of various agents at equivalent doses). In regard to the risk of delayed adverse reactions, whereas gadoterate has a macrocyclic structure and is widely considered a safe GBCA based on in vitro stability data, 25 no cases of nephrogenic systemic fibrosis have yet been reported after the sole administration of gadobenate, [26] [27] [28] and gadobenate, like gadoterate, is considered a low-risk agent for nephrogenic systemic fibrosis by the American College of Radiology and other regulatory authorities, including the US Food and Drug Administration. 29, 30 Moreover, unlike gadoterate, gadobenate has a dual route of elimination from the body, meaning that Gd 3ϩ is still eliminated via the hepatobiliary pathway in even greater amounts in patients with severely impaired renal function or end-stage renal disease. 26, 27, 31 In regard to the possibility of intracranial Gd 3ϩ deposition, the GBCAs most closely associated with this phenomenon as yet have been gadodiamide and gadopentetate dimeglumine (ie, the same GBCAs most frequently associated with unconfounded cases of nephrogenic systemic fibrosis). [19] [20] [21] [22] [23] [24] In terms of immediate-type adverse events, both gadobenate and gadoterate were safe and well-tolerated in patients with suspected or confirmed brain pathology, with no serious adverse events reported for either agent.
In common with previous studies of this type, 1-4,8,11 a principal limitation is that the clinical impact of gadobenate on patient management and outcome was not directly evaluated. Although the greater diagnostic information available with full-dose gadobenate would be expected to benefit therapeutic procedures by better defining resection margins and radiosurgical target volumes, further dedicated studies are required to prove this point conclusively. A second possible limitation is that imaging was performed only at 1.5T. On the other hand, significant superiority for gadobenate compared with the standard relaxivity agent gadopentetate dimeglumine has also been confirmed at 3T, 2 while a more recent study suggests that the potential benefits of gadobenate also extend to higher field strength systems. 32 Notably, in this latter study, the lesion enhancement achieved with half-dose gadobenate at 7T was higher than that achieved with full-dose gadobenate at 3T, suggesting the possibility for dose reduction at higher field strengths. 32 However, the use of half-dose gadobenate for imaging of the CNS would be considered an off-label application.
CONCLUSIONS
Two conclusions can be drawn from this study. First, gadobenate is significantly superior to gadoterate for qualitative and quantitative enhancement of brain lesions when these agents are administered at an equivalent dose of 0.1 mmol/kg body weight. Second, a half-dose of gadobenate (0.05 mmol/kg body weight) is equivalent to a full dose (0.1 mmol/kg body weight) of gadoterate and may prove advantageous when a clinical requirement is to administer a low GBCA dose. In demonstrating the value of half-dose gadobenate for brain tumor imaging, our study supports the findings of numerous previous studies across a range of MR imaging applications that have confirmed the diagnostic potential of gadobenate at 0.05 mmol/kg body weight. [33] [34] [35] [36] 
